| Literature DB >> 33377658 |
Athanasia Warnecke1, Jennifer Harre1, Hinrich Staecker2, Nils Prenzler1, Dirk Strunk3, Sebastien Couillard-Despres4,5, Pasquale Romanelli4, Julia Hollerweger6, Teresa Lassacher6, Daniela Auer6, Karin Pachler7, Georg Wietzorrek8, Ulrike Köhl9, Thomas Lenarz1, Katharina Schallmoser6,10, Sandra Laner-Plamberger10, Christine S Falk11, Eva Rohde6,10, Mario Gimona6,7.
Abstract
The lack of approved anti-inflammatory and neuroprotective therapies in otology has been acknowledged in the last decades and recent approaches are heralding a new era in the field. Extracellular vesicles (EVs) derived from human multipotent (mesenchymal) stromal cells (MSC) can be enriched in vesicular secretome fractions, which have been shown to exert effects (eg, neuroprotection and immunomodulation) of their parental cells. Hence, MSC-derived EVs may serve as novel drug candidates for several inner ear diseases. Here, we provide first evidence of a strong neuroprotective potential of human stromal cell-derived EVs on inner ear physiology. In vitro, MSC-EV preparations exerted immunomodulatory activity on T cells and microglial cells. Moreover, local application of MSC-EVs to the inner ear significantly attenuated hearing loss and protected auditory hair cells from noise-induced trauma in vivo. Thus, EVs derived from the vesicular secretome of human MSC may represent a next-generation biological drug that can exert protective therapeutic effects in a complex and nonregenerating organ like the inner ear.Entities:
Keywords: extracellular vesicles (EVs); inner ear; neuroprotection; spiral ganglion neurons; umbilical cord-derived mesenchymal stromal cells (UC-MSC)
Year: 2020 PMID: 33377658 PMCID: PMC7752163 DOI: 10.1002/ctm2.262
Source DB: PubMed Journal: Clin Transl Med ISSN: 2001-1326